摘要
胃癌是常见恶性肿瘤之一,是癌症相关死亡的第二大常见肿瘤.ToGA试验证实人源化抗人类表皮生长因子受体2(human epidermal growth factor receptor-2,HER2)单克隆抗体曲妥珠单抗能够有效延长HER2阳性胃癌、胃食管连接部腺癌患者的生存期,并将曲妥珠单抗联合化疗作为胃癌、胃食管连接部腺癌的标准化治疗方案.因此,精准的筛选HER2阳性的胃癌患者至关重要.本文对胃癌HER2检测的方法标准、指导方针以及一些新观点进行简要综述.
Gastric cancer is one of the most common malig- nancies and represents the second leading cause of cancer death worldwide. The ToGA trial has shown that the humanized anti-HER2 （human epidermal growth factor receptor-2） monoclonal antibody Trastuzumab is effective in prolonging survival in patients with HER2-positive carci- noma of the stomach and the gastroesophageal junction （GEJ）. Trastuzumab in combination with chemotherapy can be considered as a new standard option for patients with HER2-positive advanced gastric or gastro-oesophageal junc- tion cancer. Therefore, it is crucial to accurately screen patients with HER2-positive gastric can- cer. This article mainly discusses the recent ad- vances in HER2 testing in gastric cancer.
出处
《世界华人消化杂志》
CAS
北大核心
2013年第36期4098-4103,共6页
World Chinese Journal of Digestology
